FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280511732> ?p ?o ?g. }

• W4280511732 abstract "Abstract Background The standard of care treatment for soft tissue sarcoma of the extremities is a wide resection in combination with pre- or postoperative radiotherapy with high local control rates, sparing patients the necessity of amputation without compromising on overall survival rates. The currently preferred timing of radiotherapy is under debate. Albeit having higher rates of acute wound complications, late side effects like fibrosis, joint stiffness or edema are less frequent in preoperative compared to postoperative radiotherapy. This can be explained in smaller treatment volumes and a lower dose in the preoperative setting. Particles allow better sparing of surrounding tissues at risk, and carbon ions additionally offer biologic advantages and are preferred in less radiosensitive tumors. Hypofractionation allows for a significantly shorter treatment duration. Methods Extrem-ion is a prospective, randomized, monocentric phase II trial. Patients with resectable or marginally resectable, histologically confirmed soft tissue sarcoma of the extremities will be randomized between neoadjuvant proton or neoadjuvant carbon ion radiotherapy in active scanning beam application technique (39 Gy [relative biological effectiveness, RBE] in 13 fractions [5–6 fractions per week] in each arm). The primary objective is the proportion of therapies without wound healing disorder the first 120 days after surgery or discontinuation of treatment for any reason related to the treatment. The secondary endpoints of the study consist of local control, local progression-free survival, disease-free survival, overall survival, and quality of life. Discussion The aim of this study is to confirm that hypofractionated, preoperative radiotherapy is safe and feasible. The potential for reduced toxicity by the utilization of particle therapy is the rational of this trial. A subsequent randomized phase III trial will compare the hypofractionated proton and carbon ion irradiation in regards to local control. Trial registration ClinicalTrials.gov Identifier: NCT04946357 ; Retrospectively registered June 30, 2021." @default.
• W4280511732 created "2022-05-22" @default.
• W4280511732 creator A5000073064 @default.
• W4280511732 creator A5000911809 @default.
• W4280511732 creator A5001877436 @default.
• W4280511732 creator A5014427777 @default.
• W4280511732 creator A5019277763 @default.
• W4280511732 creator A5022223987 @default.
• W4280511732 creator A5029591543 @default.
• W4280511732 creator A5033830737 @default.
• W4280511732 creator A5034203128 @default.
• W4280511732 creator A5059600151 @default.
• W4280511732 creator A5064145691 @default.
• W4280511732 creator A5070621357 @default.
• W4280511732 creator A5078003238 @default.
• W4280511732 creator A5083079052 @default.
• W4280511732 creator A5084241424 @default.
• W4280511732 date "2022-05-12" @default.
• W4280511732 modified "2023-10-17" @default.
• W4280511732 title "Neoadjuvant irradiation of extremity soft tissue sarcoma with ions (Extrem-ion): study protocol for a randomized phase II pilot trial" @default.
• W4280511732 cites W1878715328 @default.
• W4280511732 cites W1893251984 @default.
• W4280511732 cites W1992997522 @default.
• W4280511732 cites W2005391728 @default.
• W4280511732 cites W2029409133 @default.
• W4280511732 cites W2035002792 @default.
• W4280511732 cites W2042260123 @default.
• W4280511732 cites W2049903086 @default.
• W4280511732 cites W2051346698 @default.
• W4280511732 cites W2056646032 @default.
• W4280511732 cites W2059921231 @default.
• W4280511732 cites W2062541316 @default.
• W4280511732 cites W2097183744 @default.
• W4280511732 cites W2100457375 @default.
• W4280511732 cites W2120975027 @default.
• W4280511732 cites W2127333657 @default.
• W4280511732 cites W2153477869 @default.
• W4280511732 cites W2729977398 @default.
• W4280511732 cites W2738223351 @default.
• W4280511732 cites W2742505852 @default.
• W4280511732 cites W2755560674 @default.
• W4280511732 cites W2766166076 @default.
• W4280511732 cites W2781525129 @default.
• W4280511732 cites W2799363236 @default.
• W4280511732 cites W2806116757 @default.
• W4280511732 cites W3025271415 @default.
• W4280511732 cites W3112448992 @default.
• W4280511732 cites W3127412274 @default.
• W4280511732 cites W3209179470 @default.
• W4280511732 doi "https://doi.org/10.1186/s12885-022-09560-x" @default.
• W4280511732 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35550036" @default.
• W4280511732 hasPublicationYear "2022" @default.
• W4280511732 type Work @default.
• W4280511732 citedByCount "3" @default.
• W4280511732 countsByYear W42805117322023 @default.
• W4280511732 crossrefType "journal-article" @default.
• W4280511732 hasAuthorship W4280511732A5000073064 @default.
• W4280511732 hasAuthorship W4280511732A5000911809 @default.
• W4280511732 hasAuthorship W4280511732A5001877436 @default.
• W4280511732 hasAuthorship W4280511732A5014427777 @default.
• W4280511732 hasAuthorship W4280511732A5019277763 @default.
• W4280511732 hasAuthorship W4280511732A5022223987 @default.
• W4280511732 hasAuthorship W4280511732A5029591543 @default.
• W4280511732 hasAuthorship W4280511732A5033830737 @default.
• W4280511732 hasAuthorship W4280511732A5034203128 @default.
• W4280511732 hasAuthorship W4280511732A5059600151 @default.
• W4280511732 hasAuthorship W4280511732A5064145691 @default.
• W4280511732 hasAuthorship W4280511732A5070621357 @default.
• W4280511732 hasAuthorship W4280511732A5078003238 @default.
• W4280511732 hasAuthorship W4280511732A5083079052 @default.
• W4280511732 hasAuthorship W4280511732A5084241424 @default.
• W4280511732 hasBestOaLocation W42805117321 @default.
• W4280511732 hasConcept C126838900 @default.
• W4280511732 hasConcept C136948725 @default.
• W4280511732 hasConcept C141071460 @default.
• W4280511732 hasConcept C143998085 @default.
• W4280511732 hasConcept C168563851 @default.
• W4280511732 hasConcept C2778629024 @default.
• W4280511732 hasConcept C2778715236 @default.
• W4280511732 hasConcept C509974204 @default.
• W4280511732 hasConcept C71924100 @default.
• W4280511732 hasConceptScore W4280511732C126838900 @default.
• W4280511732 hasConceptScore W4280511732C136948725 @default.
• W4280511732 hasConceptScore W4280511732C141071460 @default.
• W4280511732 hasConceptScore W4280511732C143998085 @default.
• W4280511732 hasConceptScore W4280511732C168563851 @default.
• W4280511732 hasConceptScore W4280511732C2778629024 @default.
• W4280511732 hasConceptScore W4280511732C2778715236 @default.
• W4280511732 hasConceptScore W4280511732C509974204 @default.
• W4280511732 hasConceptScore W4280511732C71924100 @default.
• W4280511732 hasFunder F4320320879 @default.
• W4280511732 hasFunder F4320330130 @default.
• W4280511732 hasIssue "1" @default.
• W4280511732 hasLocation W42805117321 @default.
• W4280511732 hasLocation W42805117322 @default.
• W4280511732 hasLocation W42805117323 @default.
• W4280511732 hasOpenAccess W4280511732 @default.
• W4280511732 hasPrimaryLocation W42805117321 @default.
• W4280511732 hasRelatedWork W1978776472 @default.
• W4280511732 hasRelatedWork W1981313983 @default.

• next